Bolt Biotherapeutics (NASDAQ:BOLT) Announces Quarterly Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) announced its quarterly earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18), FiscalAI reports. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million.

Bolt Biotherapeutics Stock Performance

Shares of Bolt Biotherapeutics stock traded up $0.03 on Tuesday, hitting $3.53. The stock had a trading volume of 13,173 shares, compared to its average volume of 26,449. Bolt Biotherapeutics has a 52-week low of $3.10 and a 52-week high of $7.20. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 1.47. The stock has a market cap of $6.81 million, a price-to-earnings ratio of -0.21 and a beta of 1.00. The company’s 50 day moving average price is $3.72 and its 200 day moving average price is $4.24.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $14.50.

Insider Buying and Selling at Bolt Biotherapeutics

In related news, CEO William Quinn sold 9,132 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $29,587.68. Following the transaction, the chief executive officer owned 25,384 shares of the company’s stock, valued at $82,244.16. This trade represents a 26.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,584 shares of company stock valued at $128,361 over the last three months. 9.40% of the stock is currently owned by corporate insiders.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.